skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

 

Pfizer Inc. CEO Ian Read has agreed to claw back price increases on 40 drugs after a phone conversation with President Donald Trump July 10, in what represents an extraordinary move by a big pharma to yield to pressure from the US president. Pfizer's decision to roll back the recent price increases comes a day after the president publicly shamed Pfizer on Twitter for increasing drug prices.

"Following an extensive discussion with President Trump today, Pfizer's Chairman and CEO Ian Read announced that it will defer the company's price increases that were effective on July 1 to give the president an opportunity to work on his blueprint to strengthen the health care system and provide more access to patients," the company said in a statement. 

Pfizer will return the prices to their pre-July 1 levels as soon as possible, and they will remain steady until the end of the year – or until the president's blueprint goes into effect, the company said. At the same time, Pfizer said the price decreases it took on five drugs would remain in effect.

President Trump took to Twitter to praise Pfizer's decision. "Pfizer is rolling back price hikes, so American patients don't pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!" The president had previously tweeted that "massive" price reductions were coming soon in response to the blueprint, but there have been no announcements yet, apart from Pfizer's rescinding of price increases and the five decreases. (Also see "Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says" - Scrip, 13 Jun, 2018.)

US Department of Health and Human Services (HHS) Secretary Alex Azar also issued a statement, calling the move a step in the right direction and a win for American patients. "I commend Pfizer for its constrictive and professional approach, and its desire to work with President Trump to be part of the solution and not part of the problem," Azar said. 

Pfizer's decision to reverse the price increases is surprising to some extent as Read has been a steady proponent of the industry's pricing practices and has not typically cowed to pressure. At the same time, the July 1 price increases represented the second round of price increases Pfizer has taken in 2018, at a time when public backlash over the high cost of drugs is intensifying.

Pfizer was reportedly one of only four companies that took a second round of price increases thus far in 2018, according to research by Morgan Stanley analysts. The other three were smaller companies: Acorda Therapeutics Inc., DepoMed Inc. and Novo Nordisk AS.

Pfizer's decision to roll back the prices on the 40 portfolio drugs could be mostly optics in the face of public shaming, but the action also raises the question of whether or not Pfizer received some assurance from President Trump in return about the implementation of the drug pricing blueprint. For example, drug manufacturers would like to see steps taken to reign in the cut pharmacy benefit managers and other partners in the distribution chain take out of the cost of drugs.There has been congressional interest in the role of PBMs and wholesalers. (Also see "US Senators Seek 'Clarity’ On Middlemen Obstructing List Price Reductions" - Pink Sheet, 4 Jul, 2018.)

Read, who has never been shy about defending Pfizer's pricing strategy publicly, said in a statement, "Pfizer shares the president's concerns for patients and commitment to providing affordable access to the medicines they need."

He also took the opportunity to reiterate that the drug industry generates hundreds of thousands of highly skilled jobs in the US, and pointed out that Pfizer has committed to reinvest $5bn in capital to expand manufacturing in the US.

"We are encouraged that the president recognizes the value our industry brings to society and our ability to fulfill our mission to discover and bring innovative new medicines to patients." 

Read also

  • Biomedtracker

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Biomedtracker

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topics Drug development landscape

  • Scrip:世界の医薬品産業ニュースサービス

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    By Brian Yang

    Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

    Topics Policy and regulation

;

Next steps

各製品の無料トライアルまたは担当スタッフによるデモンストレーションを常時受け付けています。お気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡ください。

  • 日本:         +81 3 6273 4260
  • 米国 (無料):+1 888 670 8900
  • 米国 (有料):+1 908 547 2200
  • 英国&欧州:+44 (20) 337 73737
  • 豪:      +61 2 8705 6907

お問合せフォームまたはEメールでもご質問を承っています(日本オフィス営業時間:平日9時~18時)

 

オンラインショップのレポートストアでは、常時1000以上の市場分析レポートをご提供しています。

お探しの情報が見つからない場合は、左記のお問い合わせ先までお気軽にご連絡ください。